Health Care • Biotechnology: Pharmaceutical Preparations
$41.92 ▲ +0.08
(+0.19%)
MKT CAP: $2.44B • VOL: 2.82M
52W L $38 52W H $60
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$35
MEDIAN
$47
MEAN
$48
HIGH
$57
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SUPN TAPE
SUPN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $50.72 | $48.21 | 2025-02-14 | $38.15 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $52.82 | $49.47 | 2025-02-06 | $39.40 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $47.79 | $46.11 | 2025-01-29 | $40.24 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $42.76 | — | 2025-01-17 | $41.08 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $36.89 | $39.82 | 2025-01-09 | $37.31 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $49.88 | $43.60 | 2024-12-18 | $36.47 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $40.66 | $42.34 | 2024-12-04 | $38.99 | -4.3% | 48% | C |